The renal vasoactive and systemic hypotensive effects of platelet activating factor (C16:0-PAF and C18:1-PAF) were examined in anesthetized male Wistar rats. Bolus injections of C16-PAF (0.5 - 25 ng/kg) and C18-PAF (2.5 - 200 ng/kg) into the arterial circulation of the kidney produced increases in renal blood flow (6 - 15%) before causing dose-dependant systemic hypotension (2 - 64 mmHg). The dose-response curves for renal blood flow and systemic blood pressure generated by intrarenal C18-PAF administration were approximately 7 fold to the right of the dose-response curves generated by C16-PAF. Intrarenal injections of vehicle or the biologically inactive enantiomer C16-DPAF (25 - 200 ng/kg) did not affect renal blood flow or systemic blood pressure. These results suggest that C16:0-PAF is a more potent renal vasodilator and hypotensive lipid than C18:1-PAF.
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Pharmacology, Toxicology and Pharmaceutics(all)